Xcout Intel
MELIUS HEALTH CARE SOLUTIONS, INC. competitors & alternatives
The 12 closest competitors and alternatives to MELIUS HEALTH CARE SOLUTIONS, INC. among pharmaceuticals companies — ranked by similarity to what MELIUS HEALTH CARE SOLUTIONS, INC. actually does, not by market-cap band.
Subscribe to see MELIUS HEALTH CARE SOLUTIONS, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About MELIUS HEALTH CARE SOLUTIONS, INC.
Melius Pharma is a Swedish clinical-stage pharmaceutical company that develops new treatments for severe diseases with high unmet clinical needs. Its primary focus is the development of its lead candidate, ME-015, as a treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
MELIUS HEALTH CARE SOLUTIONS, INC. at a glance
MELIUS HEALTH CARE SOLUTIONS, INC. is a pharmaceuticals company headquartered in United States. Its most recent funding round raised $408,333 in July 2017. Xcout tracks 5 named people at MELIUS HEALTH CARE SOLUTIONS, INC., including Peter Heinrich (Chairman of the Board).
MELIUS HEALTH CARE SOLUTIONS, INC. leadership
- Peter HeinrichChairman of the Board
- Christer FåhraeusBoard Member
- Christine LemkeBoard Member
- Karl TobiesonBoard Member
- Niels SkjørbaekBoard Member
MELIUS HEALTH CARE SOLUTIONS, INC. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $408,333 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 MELIUS HEALTH CARE SOLUTIONS, INC. competitors
Ranked by semantic similarity — how close each company is to MELIUS HEALTH CARE SOLUTIONS, INC. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Similar pharmaceuticals company
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Similar pharmaceuticals company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Similar pharmaceuticals company
Cinclus Pharma is a clinical-stage pharmaceutical company based in Stockholm, Sweden. The firm is focused on achieving a paradigm shift in the treatment of acid-related diseases by developing and advancing targeted drug candidates like GERD treatments.
Pharmaceuticals & Biotechnology
Promore Pharma is a Stockholm-based biopharmaceutical company listed on the Nasdaq First North exchange. The company specializes in developing therapeutic peptides and first-in-category treatments, focusing particularly on scar management.
Similar pharmaceuticals company
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Similar pharmaceuticals company
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Similar pharmaceuticals company
Pila Pharma AB is a clinical-stage biotechnology company that develops oral TRPV1 antagonists as potential treatments for obesity and diabetes. The company serves patients suffering from these metabolic conditions by advancing innovative, non-injectable drug candidates through preclinical and clinical research.
Similar pharmaceuticals company
Egetis Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of treatments for serious, rare diseases with high unmet medical needs. Operating internationally, the public company has its headquarters in Stockholm, Sweden, alongside a growing presence in the United States. Its clinical pipeline targets specialized therapeutic indications to improve patient outcomes.
Similar pharmaceuticals company
Purpose Pharma International AB is a European pharmaceutical company headquartered in Stockholm, Sweden. The firm is dedicated to giving people with rare diseases a better quality of life.
Pharmaceuticals (Drug Delivery)
Camurus is an international pharmaceutical company that develops and provides innovative, long-acting treatments for patients with severe and chronic conditions. The company focuses on therapeutic areas including the central nervous system, rare diseases, endocrinology, oncology, and supportive care.
Similar pharmaceuticals company
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of MELIUS HEALTH CARE SOLUTIONS, INC. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for MELIUS HEALTH CARE SOLUTIONS, INC.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →